First Manhattan’s Aldeyra Therapeutics ALDX Stock Holding History

First Manhattan’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-34,745	Closed	-$58.7K	–	746
2026 Q1	$58.7K	Hold	34,745	–	–	﹤0.01%	748
2025 Q4	$180K	Hold	34,745	–	–	﹤0.01%	706
2025 Q3	$181K	Hold	34,745	–	–	﹤0.01%	690
2025 Q2	$133K	Hold	34,745	–	–	﹤0.01%	680
2025 Q1	$200K	Hold	34,745	–	–	﹤0.01%	648
2024 Q4	$173K	Hold	34,745	–	–	﹤0.01%	659
2024 Q3	$187K	Hold	34,745	–	–	﹤0.01%	656
2024 Q2	$115K	Hold	34,745	–	–	﹤0.01%	647
2024 Q1	$114K	Hold	34,745	–	–	﹤0.01%	749
2023 Q4	$122K	Hold	34,745	–	–	﹤0.01%	730
2023 Q3	$232K	Hold	34,745	–	–	﹤0.01%	634
2023 Q2	$292K	Hold	34,745	–	–	﹤0.01%	590
2023 Q1	$345K	Hold	34,745	–	–	﹤0.01%	577
2022 Q4	$242K	Hold	34,745	–	–	﹤0.01%	654
2022 Q3	$185K	Hold	34,745	–	–	﹤0.01%	708
2022 Q2	$138K	Hold	34,745	–	–	﹤0.01%	785
2022 Q1	$154K	Hold	34,745	–	–	﹤0.01%	807
2021 Q4	$138K	Hold	34,745	–	–	﹤0.01%	818
2021 Q3	$305K	Sell	34,745 -1,001	-3%	-$9.19K	﹤0.01%	660
2021 Q2	$405K	Buy	+35,746	New	+$430K	﹤0.01%	599
2020 Q3	–	Sell	-350	Closed	-$1K	–	1324
2020 Q2	$1K	Buy	+350	New	+$1.28K	﹤0.01%	1337

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

First Manhattan's ALDX Position: Q2 2026 in Review

First Manhattan sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 34,745 shares — an estimated $58.7K sold.

First Manhattan first reported a position in ALDX in Q2 2020 and held it in 21 quarters. The position peaked at $405K in Q2 2021. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

First Manhattan reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
First Manhattan sold 34,745 Aldeyra Therapeutics shares in Q2 2026, an estimated $58.7K.
First Manhattan first reported a position in Aldeyra Therapeutics in Q2 2020 and held it in 21 quarters.
First Manhattan's Aldeyra Therapeutics position peaked at $405K in Q2 2021.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on First Manhattan's 13F filing for Q2 2026, filed 14 Aug 2026.